ABSTRACT
Inflammation and oxidative damage play direct roles in coronary artery disease. C-reactive protein (CRP) is currently the best available marker of inflammation, and statins can potentially reduce coronary inflammation. Until now, CRP testing has been somewhat controversial in the context of cardiovascular disease, as has statin treatment specifically to treat inflammation. However, three recent studies showed that early and aggressive treatment with statins reduces future cardiovascular and cerebrovascular events in patients with acute coronary syndromes; another study showed that aggressive statin treatment leads to regression of stable coronary artery disease. In all the studies, the benefit correlated with reductions in CRP.
Footnotes
↵* Dr. Shishehbor is supported in part by the National Institutes of Health, National Institute of Child Health and Human Development, Multidisciplinary Clinical Research Career Development Programs Grant K12 HD049091.
↵† Dr. Bhatt has disclosed receiving honoraria from the Astra Zeneca and Bristol Myers Squibb corporations for teaching, speaking, and consulting.
- © 2006 The Cleveland Clinic Foundation. All Rights Reserved.